相关实验视频

Updated: Jun 7, 2025

Automated Measurement of Pulmonary Emphysema and Small Airway Remodeling in Cigarette Smoke-exposed Mice

Automated Measurement of Pulmonary Emphysema and Small Airway Remodeling in Cigarette Smoke-exposed Mice

Published on: January 16, 2015

银化物Rg1通过调节PERK/ATF4轴来抑制内 плазма网膜应激应激,改善COPD中香烟烟雾引起的铁亡

Wei Tan¹, Zicheng Liang¹, Xiaoning Tan²

¹Graduate School, Hunan University of Chinese Medicine, Changsha, China.

Biochemical and biophysical research communications

|November 12, 2024

概括

银化物Rg1通过抑制细胞死亡途径铁亡,缓解慢性阻塞性肺病 (COPD). 这项研究证明了其潜在的治疗效果,通过在COPD模型中调节细胞内膜网膜应激 (ERS).

科学领域:

细胞生物学细胞生物学
药理学药理学是指药理学的学科.
呼吸系统医学呼吸系统医学

背景情况:

铁死与慢性阻塞性肺病 (COPD) 病原发生有关.
人参化物Rg1在COPD的治疗潜力及其涉及ferroptosis抑制的机制仍然不清楚.

研究的目的:

为了调查金氏化物Rg1是否可以改善香烟烟雾引起的COPD.
为了确定金氏化物Rg1是否通过抑制铁亡来发挥其作用.

主要方法:

使用的BEAS-2B细胞暴露在香烟烟雾溶液 (CSE) 和香烟烟雾诱导的COPD的小鼠模型中.
评估了细胞活力,细胞内网膜应激 (ERS),线粒体功能,活性氧物种 (ROS),铁含量和蛋白质表达.
向慢性肺炎小鼠注射Rg1的金氏化物和PERK抑制剂 (GSK),并评估肺组织病理和分子标记.

主要成果:

CSE/CS暴露增加了ERS标志物 (例如,GRP78) 和减少了抗氧化剂标志物 (GPX4,GSH).
在体外和体外模型中,丁胺Rg1治疗改善了肺气和炎症.
金色化物Rg1通过调节ERS来抑制铁亡,正如PERK抑制剂实验所证明的那样.

结论:

银化物Rg1减轻了香烟烟雾引起的COPD.
治疗效果涉及抑制内 плазма网膜应激和铁化.
银化物Rg1调节PERK/ATF4轴以达到这些效果.

关键词:

慢性阻塞性肺病是一种慢性阻塞性肺病.细胞内膜网膜应激压力是什么铁性化 (ferroptosis) 是一种人参化物 Rg1 佩克 (Perk) 是一种可怕的东西.

更多相关视频

Methods to Evaluate Cytotoxicity and Immunosuppression of Combustible Tobacco Product Preparations

Methods to Evaluate Cytotoxicity and Immunosuppression of Combustible Tobacco Product Preparations

Published on: January 10, 2015

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics

Published on: March 15, 2024

相关概念视频

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation

COPD: Pathogenesis and Clinical Features

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...

Chronic Obstructive Pulmonary Disease-I: Introduction

Chronic Obstructive Pulmonary Disease-I: Introduction

Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.

COPD: Management Using Bronchodilators and Corticosteroids

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...